November of 2009, I suggested that rumors about Dr. Scholl's going to Reckitt seemed. . . unlikely.
Apparently, at some point recently, Reckitt acquired the non-Americas rights to the brand. Now Reckitt is selling those same rights on, to a private equity buyer. So, either I missed a step (an intervening sale -- in 2009 to 2013 timeframe), or this is a new transfer. No matter, Reuters has it all, this morning.
Of course, the US -- and rest of the Americas -- rights will belong to Bayer, as agreed this spring. Per Reuters, then:
. . . .German private equity firm Aurelius said on Monday it is buying Reckitt Benckiser's Scholl shoe business in its efforts to expand internationally, betting on the brand's growth potential.
Under the agreement, Aurelius would acquire the international rights for the Scholl footwear business, excluding North and South America.
The rights to that business in the Americas will go to German drugmaker Bayer as part of its $14 billion purchase of Merck & Co's consumer health business.
Aside from the Scholl shoe business, which is known for its focus on comfort, Reckitt Benckiser has a Scholl-branded footcare business that includes insoles and blister bandages. . . .
The cash Merck got for these legacy Schering-Plough Scholls lines is simply fantastic. Top dollar. Really a coup for Mr. Frazier, at those high valuations. So. . . Onward!